[go: up one dir, main page]

AR088907A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR088907A1
AR088907A1 ARP120104341A ARP120104341A AR088907A1 AR 088907 A1 AR088907 A1 AR 088907A1 AR P120104341 A ARP120104341 A AR P120104341A AR P120104341 A ARP120104341 A AR P120104341A AR 088907 A1 AR088907 A1 AR 088907A1
Authority
AR
Argentina
Prior art keywords
immunogenic composition
composition according
tlr
antigen
agonists
Prior art date
Application number
ARP120104341A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR088907A1 publication Critical patent/AR088907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones inmunogénicas que comprenden uno o más antígenos y un coadyuvante para su uso en inmunización cutánea en las que dicho coadyuvante es un agonista de TLR-5. Reivindicación 2: Una composición inmunogénica de acuerdo con la reivindicación 1 en la que dicha composición inmunogénica comprende adicionalmente uno o más coadyuvantes adicionales seleccionados del grupo que consiste en: agonistas de TLR-4, agonistas de TLR7/8, o una saponina inmunológicamente activa. Reivindicación 3: Una composición inmunogénica de acuerdo con cualquier reivindicación precedente que se administra en forma de un parche. Reivindicación 4: Una composición inmunogénica de acuerdo con cualquier reivindicación precedente que se administra usando un dispositivo de aguja corta. Reivindicación 5: Una composición inmunogénica de acuerdo con cualquier reivindicación precedente en la que dicho agonista de TLR-5 es una flagelina o un fragmento de la misma que tiene actividad TLR-5. Reivindicación 8: Una composición inmunogénica de acuerdo con cualquier reivindicación precedente en la que el antígeno se deriva del virus de la hepatitis B, en particular en la que el antígeno es antígeno de superficie de la hepatitis B (HBsAg).
ARP120104341A 2011-11-20 2012-11-19 Vacuna AR088907A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1119999.9A GB201119999D0 (en) 2011-11-20 2011-11-20 Vaccine

Publications (1)

Publication Number Publication Date
AR088907A1 true AR088907A1 (es) 2014-07-16

Family

ID=45475426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104341A AR088907A1 (es) 2011-11-20 2012-11-19 Vacuna

Country Status (10)

Country Link
US (1) US20140322271A1 (es)
EP (1) EP2780038A1 (es)
JP (1) JP2014533673A (es)
CN (1) CN103957934A (es)
AR (1) AR088907A1 (es)
BR (1) BR112014012043A2 (es)
CA (1) CA2855797A1 (es)
GB (1) GB201119999D0 (es)
IN (1) IN2014CN03454A (es)
WO (1) WO2013072518A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2750683T (pt) 2011-10-03 2018-06-26 Mx Adjuvac Ab Nanopartículas, processo de preparação e seu uso como transportadores para moléculas hidrofóbicas anfipáticas no domínio da medicina, incluindo tratamento de cancro e compostos relacionados a alimentos
EP3127552B1 (en) * 2014-04-04 2019-01-23 FUJIFILM Corporation Inactivated whole virion vaccine-containing microneedle array preparation and method for administering the same
CN106362144B (zh) * 2016-10-31 2021-02-09 武汉三利生物技术有限公司 呼吸道合胞病毒疫苗
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
WO2018175854A1 (en) * 2017-03-23 2018-09-27 The Children's Medical Center Corporation Methods and compositions relating to adjuvants
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
AU2021300632A1 (en) 2020-07-02 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of achieving HIV viral remission using long-acting antiretroviral agents

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040087992A1 (en) 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
JP2006503825A (ja) * 2002-09-03 2006-02-02 フォンダシオン ユーロバク アジュバント
BRPI0412202A (pt) * 2003-07-02 2006-08-22 Alza Corp emplastro para imunização tendo um arranjo de microprojeções, e método
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
KR20050073865A (ko) * 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
KR101224257B1 (ko) 2004-11-18 2013-01-18 쓰리엠 이노베이티브 프로퍼티즈 컴파니 마이크로니들 어레이를 코팅하기 위한 마스킹 방법
AU2005306372B2 (en) 2004-11-18 2011-01-06 Kindeva Drug Delivery L.P. Method of contact coating a microneedle array
EP1824510B1 (en) * 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
WO2006075689A1 (ja) * 2005-01-14 2006-07-20 Fujikura Ltd. 医薬物運搬用器具とその製造方法
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
JP2008029710A (ja) * 2006-07-31 2008-02-14 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai マイクロニードル型パッチ及びその製造方法
EP2121111B1 (en) 2007-01-22 2018-03-14 Corium International, Inc. Applicators for microneedle arrays
US8911749B2 (en) 2007-04-16 2014-12-16 Corium International, Inc. Vaccine delivery via microneedle arrays
ES2820335T3 (es) 2007-04-16 2021-04-20 Corium Inc Matrices de microagujas coladas con disolvente que contienen agente activo
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
BRPI0914691A2 (pt) 2008-06-25 2015-10-20 Inserm Inst Nat De La Santé Et De La Rech Médicale composto imunoadjuvante, composição, uso de um composto imunoadjuvante, ácido nucléico, vetor recombinante, e, célula hospedeira
CA2733750C (en) 2008-08-11 2016-10-11 Glaxosmithkline Llc Novel adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8486408B2 (en) * 2008-10-03 2013-07-16 Emory University Methods for the treatment of graft-versus-host disease
ES2656813T3 (es) 2008-10-24 2018-02-28 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
US20110006458A1 (en) 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
WO2011095649A1 (es) * 2010-02-02 2011-08-11 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Uso de flagelinas del género marinobacter como adyuvantes vacunales
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine

Also Published As

Publication number Publication date
US20140322271A1 (en) 2014-10-30
IN2014CN03454A (es) 2015-07-03
CN103957934A (zh) 2014-07-30
BR112014012043A2 (pt) 2017-05-16
EP2780038A1 (en) 2014-09-24
JP2014533673A (ja) 2014-12-15
CA2855797A1 (en) 2013-05-23
GB201119999D0 (en) 2012-01-04
WO2013072518A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
AR088907A1 (es) Vacuna
CU20190030A7 (es) Composiciones de vacunas antineumocócicas polivalentes que comprenden conjugados de polisacárido-proteína
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
MX2016016533A (es) Combinaciones inmunogenas.
PE20201443A1 (es) Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
PE20120319A1 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico
AR092896A1 (es) Composiciones inmunogenicas
AR101455A1 (es) Molécula portadora
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX384875B (es) Método para obtener una vacuna de mycoplasma.
AR103544A1 (es) FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
AR080111A1 (es) Metodos y composiciones de inmunizacion
AR061894A1 (es) Vacunas para malaria
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2019003116A (es) Nueva vacuna contra la gripe porcina.
BR112023019301A2 (pt) Formulações de vacina de coronavírus
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
MX366051B (es) Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
MX2024006589A (es) Formulaciones de vacunas contra el coronavirus.

Legal Events

Date Code Title Description
FB Suspension of granting procedure